The Impact Of Different EGFR Status On The Clinical Features And Survival Of Brain Metastasis In Patients With Non-small Cell Lung Cancer

Objective: Our study explored the different clinical characteristics of brain metastasis in NSCLC patients with different epidermal growth factor receptor(EGFR)mutation status and the impact of different EGFR status on overall survival after brain metastasis.Methods: A retrospective study was conducted in 67 pathological confirmed NSCLC patients who were diagnosed between April 10,2011 to June10,2014.EGFR mutation was tested by amplification refractory mutation system(ARMS).We analyzed the impact of different EGFR status on the clinical features and overall survival after brain metastasis in patients with Non-small cell lung cancer.Results:1.Patients with diagnosed brain metastases at initial time were more common in patients with EGFR mutations,and patients with brain metastases during treatment were more common in patients with EGFR wild type(P<0.05).Multiple brain metastases(>3)were more common in patients with EGFR mutant NSCLC,whereas single brain metastases(1~3)were more common inEGFR wild type patients(P<0.05).Brain metastases of EGFR mutant NSCLC patients were more common in small lesions(1~3cm)than in wild type patients(P <0.05).Gender,age,smoking history,ECOG score,primary tumor stage,regional lymph node stage,primary lung lesion location,location of brain metastases,symptoms of brain metastases,extracranial metastases was no significant difference in patients in different EGFR mutation status(P> 0.05).2.The BM-OS of patients with EGFR mutant was significantly longer than patients with EGFR wild-type patients(12.3 months vs.6.7 months,P <0.05).The BM-OS of patients with exon 19 deletion was significantly longer than the patients with 21L858 R and EGFR wild-type patients(15.8 months vs.10.8months vs.6.7 months,P <0.05).Conclusion: Patients of brain metastases with different EGFR mutations have different clinical characteristics.Different treatment methods have an impact on the long-term survival of NSCLC after diagnosed brain metastases.